

Linear Models**The GLM Procedure**

Class Level Information		
Class	Levels	Values
Treatment	2	1 2
Histologic stage	4	1 2 3 4

Number of Observations Read	418
Number of Observations Used	310

Linear Models

The GLM Procedure

Type III Estimable Functions						
Effect	Coefficients					
	Bilirubin	Albumin	Urine copper	Alkaline phosphatase	Treatment	Histologic stage
Intercept	0	0	0	0	0	0
Bilirubin	L2	0	0	0	0	0
Albumin	0	L3	0	0	0	0
Urine copper	0	0	L4	0	0	0
Alkaline phosphatase	0	0	0	L5	0	0
Treatment 1	0	0	0	0	L6	0
Treatment 2	0	0	0	0	-L6	0
Histologic stage 1	0	0	0	0	0	L8
Histologic stage 2	0	0	0	0	0	L9
Histologic stage 3	0	0	0	0	0	L10
Histologic stage 4	0	0	0	0	0	-L8-L9-L10

Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	8	156176513.6	19522064.2	25.03	<.0001
Error	301	234809724.6	780098.8		
Corrected Total	309	390986238.2			

R-Square	Coeff Var	Root MSE	Survival Time Mean
0.399442	43.92871	883.2320	2010.603

Source	DF	Type III SS	Mean Square	F Value	Pr > F
Bilirubin	1	19861897.12	19861897.12	25.46	<.0001
Albumin	1	21115888.75	21115888.75	27.07	<.0001
Urine copper	1	8644160.97	8644160.97	11.08	0.0010
Alkaline phosphatase	1	22846843.51	22846843.51	29.29	<.0001
Treatment	1	348782.16	348782.16	0.45	0.5042
Histologic stage	3	11550922.59	3850307.53	4.94	0.0023


Parameter	Estimate	Standard Error	t Value	Pr > t
Intercept	-482.0609246	491.0779621	-0.98	0.3271
Bilirubin	-65.3756025	12.9562742	-5.05	<.0001
Albumin	707.7173371	136.0285109	5.20	<.0001
Urine copper	-2.2731262	0.6828682	-3.33	0.0010
Alkaline phosphatase	0.1295325	0.0239354	5.41	<.0001
Treatment 1	-67.9547142	101.6289061	-0.67	0.5042
Treatment 2	0.0000000	.	.	.
Histologic stage 1	820.4604496	247.0720862	3.32	0.0010
Histologic stage 2	416.2650451	147.7617466	2.82	0.0052
Histologic stage 3	211.9791347	126.1534276	1.68	0.0939
Histologic stage 4	0.0000000	.	.	.

Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.




Linear Models

The GLM Procedure

Dependent Variable: Survival Time

Note: The X'X matrix has been found to be singular, and a generalized inverse was used to solve the normal equations. Terms whose estimates are followed by the letter 'B' are not uniquely estimable.



Linear Models

The GLM Procedure

Level of Treatment	N	Survival Time		Bilirubin		Albumin	
		Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
1	157	2023.21019	1093.44378	2.88407643	3.63798531	3.51878981	0.44358440
2	153	1997.66667	1159.68198	3.66862745	5.29348496	3.52496732	0.39689274

Urine copper		Alkaline phosphatase	
Mean	Std Dev	Mean	Std Dev
97.6433121	90.5900892	2024.99363	2189.92686
97.6535948	80.4864585	1948.56601	2107.45461

Level of Histologic stage	N	Survival Time		Bilirubin		Albumin	
		Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
1	16	2940.25000	1002.74527	1.07500000	1.33341666	3.73937500	0.29616367
2	66	2409.93939	1056.35143	2.15151515	3.84580660	3.63181818	0.36117717
3	120	2140.86667	1000.19163	2.90000000	4.34472538	3.63400000	0.36675364
4	108	1484.10185	1093.73307	4.69351852	5.06245615	3.29777778	0.43614568

Urine copper		Alkaline phosphatase	
Mean	Std Dev	Mean	Std Dev
62.812500	47.091710	1694.21250	1895.16041
68.030303	53.795616	1827.87576	2157.33425
92.075000	75.003548	2082.12833	2353.80505
127.101852	105.871898	2022.70370	1942.43702

Linear Models

The GLM Procedure

Level of Treatment	N	Survival Time		Bilirubin		Albumin	
		Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
1	157	2023.21019	1093.44378	2.88407643	3.63798531	3.51878981	0.44358440
2	153	1997.66667	1159.68198	3.66862745	5.29348496	3.52496732	0.39689274

Urine copper		Alkaline phosphatase	
Mean	Std Dev	Mean	Std Dev
97.6433121	90.5900892	2024.99363	2189.92686
97.6535948	80.4864585	1948.56601	2107.45461